Theranostic Strategy Against Plaque Angiogenesis**Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.

JACC: Cardiovascular Imaging

Volumn 1, Issue 5, 2008, Pages 635-637

  Arbustini, Eloisa ^a   Gambarin, Fabiana Isabella ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

angiogenesis; plaque hemorrhage; theranostic

Indexed keywords

ALBUMIN; ATORVASTATIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GLYCOPHORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; NANOPARTICLE; PACLITAXEL; VITRONECTIN RECEPTOR;

ACUTE CORONARY SYNDROME; ANTIANGIOGENIC THERAPY; AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; MOLECULAR IMAGING; MONOTHERAPY; NANOMEDICINE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOSIS; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ATHEROSCLEROSIS; CARBOCYANINES; CYCLOHEXANES; DRUG CARRIERS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FATTY ACIDS, UNSATURATED; HEPTANOIC ACIDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; SESQUITERPENES; TIME FACTORS;

EID: 51549096548     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.07.007     Document Type: Editorial

References (23)

1. Thim T., Hagensen M.K., Bentzon J.F., and Falk E. From vulnerable plaque to atherothrombosis. J Intern Med 263 (2008) 506-516
2. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25 (2005) 2054-2061
3. Daniels G. Functional aspects of red cell antigens. Blood Rev 13 (1999) 14-35
4. Arbustini E., Morbini P., D'Armini A.M., et al. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart 88 (2002) 177-182
5. Kolodgie F.D., Gold H.K., Burke A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349 (2003) 2316-2325
6. Sumer B., Gao J., Tenaglia A.N., Peters K.G., Sketch Jr. M.H., and Annex B.H. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 135 (1998) 10-14
7. Jeziorska M., and Woolley D.E. Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development. Hum Pathol 30 (1999) 919-925
8. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
9. Moreno P.R., Purushothaman K.R., Fuster V., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110 (2004) 2032-2038
10. Koutouzis M., Nomikos A., Nikolidakis S., et al. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 192 (2007) 457-463
11. Liu S., Widom J., Kemp C.W., Crews C.M., and Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282 (1998) 1324-1327
12. Takada Y., Ye X., and Simon S. The integrins. Genome Biol 8 (2007) 215
13. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharmacol 3 (2006) 472-487
14. McQuade P., and Knight L.C. Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). Q J Nucl Med 47 (2003) 209-220
15. Plopper G.E., McNamee H.P., Dike L.E., Bojanowski K., and Ingber D.E. Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. Mol Biol Cell 6 (1995) 1349-1365
16. Espina V., Wulfkuhle J., Calvert V.S., Liotta L.A., and Petricoin III E.F. Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol Biol 441 (2008) 113-128
17. Sumer B., and Gao J. Theranostic nanomedicine for cancer. Nanomed 3 (2008) 137-140
18. Winter P.M., Morawski A.M., Caruthers S.D., et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108 (2003) 2270-2274
19. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., and Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999) 1726-1732
20. Herbst R.S., Madden T.L., Tran H.T., et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20 (2002) 4440-4447
21. Winter P.M., Neubauer A.M., Caruthers S.D., et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2103-2109
22. Winter P.M., Caruthers S.D., Zhang H., Williams T.A., Wickline S.A., and Lanza G.M. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J Am Coll Cardiol Img 1 (2008) 624-634
23. http://clinicaltrials.gov/ct2/results?term=nanoparticles&pg=1 ClinicalTrials.gov. Accessed July 21, 2008.